Brief: Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer
31/05/2025 13:07
May 31 (Reuters) - Xilio Therapeutics Inc XLO.O: XILIO THERAPEUTICS ANNOUNCES UPDATED PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER XILIO THERAPEUTICS INC - 26% RESPONSE RATE IN METASTATIC MSS CRC WITHOUT LIVER METASTASES XILIO THERAPEUTICS INC - VILASTOBART AND ATEZOLIZUMAB SHOW WELL-TOLERATED SAFETY PROFILE Source text: ID:nGNX9T0NBf Further company coverage: XLO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla